Mexicor, capsules 100 mg 20 pcs

Mexicolor^® reduces oxidative stress by inhibiting free-radical lipid peroxidation and increasing the activity of the antioxidant enzyme system. Improves cellular energy exchange by activating the energy-synthesizing functions of mitochondria, increasing compensatory activation of aerobic glycolysis and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with increased delivery and consumption of succinate by cells, realization of the phenomenon of rapid oxidation of succinate acid by succinate dehydrogenase, as well as with activation of the mitochondrial respiratory chain. Upon dissociation of Mexicor^® in the cell into succinate and 3-oxypyridine derivative (base), the base exhibits antioxidant effect that stabilizes cell membranes and restores functional activity of cells.

The action of the drug is based on its antioxidant activity, the ability to inhibit free-radical processes (whose pronounced intensification is observed during ischemia and myocardial necrosis, especially during reperfusion) and reduces the damaging effects of free radicals on cardiomyocytes.

It decreases cell membrane viscosity and increases its fluidity and modulates membrane-bound enzymes (calcium-independent FDE, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which help to maintain the structural and functional integrity of biomembranes and improve neurotransport and synaptic transmission. It improves metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.

It improves functional state of ischemic myocardium, cardiac contractile function, and reduces manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction, which is a significant reserve for increasing the contractility of the heart in patients with CHD complicated by heart failure.

In patients with stable angina pectoris increases exercise tolerance and antianginal activity of nitro medicines, improves rheological properties of blood. Addition of Mexicor^® to standard therapy of CHD improves clinical condition of patients, increases exercise tolerance and improves quality of life.

Mexicor^® stabilizes membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculatory disorders in the early stages of atherogenesis, has hypolipidemic effect, reduces total cholesterol and low-density lipoproteins (LDL).

Mexicor ^® has neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases resistance of cerebral blood circulation in hypoperfusion, prevents reduction of cerebral blood flow in the reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by inhibiting the depletion of carbohydrate stores, blocking the post-ischemic fall in glucose and oxygen utilization by the brain and preventing the progressive accumulation of lactate. At the same time the indicators of autoregulatory reactions of cerebral vessels are improved.

Mexicor^® has nootropic properties, prevents and reduces learning and memory disorders of acute and chronic cerebral vascular diseases, mild and moderate cognitive disorders of various genesis, has an antioxidant effect, increases attention concentration and performance.

Inclusion of Mexicor^® in complex therapy of patients with acute stroke reduces clinical manifestations of stroke and improves rehabilitation period.

Mexicor^® has a selective, non-sedative and myorelaxative anxiolytic effect, eliminates anxiety, fear, tension and restlessness and improves adaptation and emotional status.

Indications

Impaired cerebral circulation, Myocardial infarction, Exposure to adverse factors, Atherosclerosis, Cardialgia (heart pain), Dizziness, Vascular disorders, Asthenia, Pain in the heart

• ischemic heart disease (in complex therapy;
• ischemic stroke (in complex therapy;
• Eschemic stroke.li>ischemic heart disease (as part of complex therapy);
• ischemic stroke (as part of complex therapy);
• discirculatory encephalopathy;
• mild and moderate cognitive disorders.

.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

Active substance:

Ethylmethylhydroxypyridine succinate (in terms of 100% substance) 100 mg;

Ancillary substances:

Potato starch, 54.5 mg;

Povidone (low molecular weight medical PVP 12600±2700), 4 mg;

Lactose (milk sugar) – 40 mg;

Magnesium stearate – 0.5 mg;

MCC – 1 mg;

Hard gelatin capsule:

Titanium dioxide (E171), 1.22 mg; gelatin, 59.3189 mg; Sunset Yellow dye (E110), 0.0036 mg; quinoline yellow dye (E104), 0.4575 mg;

How to take, the dosage

Ingestion.

Start treatment with a dose of 100 mg (1 capsule) 3 times a day, gradually increasing the dose depending on the clinical course of the disease and tolerance of the therapy. The maximum daily dose should not exceed 800 mg, a single dose – 200 mg. The daily dose of the drug should preferably be divided into several doses during the day. The course therapy with the drug is ended gradually, reducing the daily dose of the drug by 100 mg (1 capsule).

The course of therapy in patients with coronary artery disease and cerebral circulation disorders should be at least 1.5-2 months. The repeated courses (as recommended by the doctor) should be carried out in the spring and fall periods.

In the complex therapy of discirculatory encephalopathy, mild and moderate cognitive disorders, the drug is prescribed without limiting the duration of treatment at a dose of 100 mg 3-4 times a day.

Special Instructions

During treatment, caution should be exercised when driving motor vehicles and engaging in other potentially dangerous activities that require increased concentration and quick psychomotor reactions.

Contraindications

• high sensitivity to the drug
• acute hepatic and renal dysfunction
• pregnancy;
• breastfeeding period;
• age below 18 years of age (efficacy and safety not established).

.

Overdose

Symptoms: sleep disturbance (insomnia), in rare cases – slight and transient (up to 1.5-2 hours) increase in BP.

Treatment: the development of overdose symptoms, as a rule, does not require the use of stopping drugs, the above symptoms of sleep disturbances disappear on their own within 24 hours.

In particularly severe cases, the use of one of the sleeping pills and anxiolytics for oral administration (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg) is recommended. In case of excessive rise in BP, prescription of hypotensive drugs (under control of BP).

Similarities

Mexidol, Mexifin, Mexiprim, Neurox, Medomexi, Evrin, MetucinVel, Neuromexol